Serum Insulin-like Growth Factor-II Is Associated with Poor Poststroke Outcomes in Males: A Secondary Analysis.

Christian Glamheden, N David Åberg, Gustaf Gadd, Daniel Åberg

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christian GlamhedenDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, 41390 Gothenburg, Sweden.

N David ÅbergDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, 41390 Gothenburg, Sweden.ORCID 0000-0002-1474-5666

Gustaf GaddDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, 41390 Gothenburg, Sweden.

Daniel ÅbergDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, 41390 Gothenburg, Sweden.ORCID 0000-0003-0517-6331

Funding

Edit JacobsonEmelle, Lars Hierta, and John and Brit Wennerström foundationsMagnus Bergvallthe Göteborg Foundation for Neurological Researchthe Rune and Ulla Amlöv Foundationthe Swedish Heart Lung Foundation 20220184the Swedish Medical Society (Svenska Läkaresällskapet)the Swedish Research Council 2021-01114the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement ALFGBG-1005813the Swedish Stroke Association

6 · The paper itself

Abstract

The insulin-like growth factor (IGF) system has significance for poststroke outcomes. Previously, we reported that low serum IGF-II (s-IGF-II) in the acute phase is associated with poststroke mortality, and that IGF-II is lower among males. Given the known interactions of the IGF system and estrogen receptor signaling, s-IGF-II may have sex-specific effects. In this study, we conducted a secondary analysis of sex differences in s-IGF-II and poststroke functional outcomes and mortality after ischemic stroke (IS) in the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS, males;

Indexed as

Insulin-Like Growth Factor IIIschemic StrokeStrokeAgedAged, 80 and overBiomarkersFemaleHumansInsulin-Like PeptidesMaleMiddle AgedPrognosisSex FactorsBiomarkersIGF2 protein, humanInsulin-Like Growth Factor IIInsulin-Like Peptidesfunctional outcomeinsulin-like growth factor-IImortalitysexstroke severity

Identifiers

PMID40564988

DOI10.3390/ijms26125525

PMCPMC12192941

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.